Trial Profile
A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Senrebotase (Primary)
- Indications Postherpetic neuralgia
- Focus Therapeutic Use
- 15 May 2012 Additional location (Poland) added as reported by ClinicalTrials.gov.
- 15 May 2012 Actual patient number is 294 according to ClinicalTrials.gov.
- 15 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.